Fertility Market Size, Share, Growth, Trends, Report 2024 to 2033

Fertility Market Size and Growth 2024 to 2033

The global fertility market size was valued at USD 41.10 billion in 2024 and is expected to be worth around USD 74.24 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.78% from 2024 to 2033.

The fertility market has been experiencing steady growth in recent years, driven by various factors such as rising awareness about infertility treatments, advancements in assisted reproductive technologies (ART), and the increasing prevalence of delayed parenthood. The rising number of individuals and couples seeking fertility assistance, especially in developed countries, has contributed to the market's expansion. Fertility clinics, genetic testing services, egg freezing technologies, and fertility drugs have become more widely available, fueling the industry's growth. Additionally, societal changes, such as a shift in family planning practices, also contribute to the growing demand for fertility services. The market is projected to continue expanding due to factors like advancements in biotechnology, increasing investments in research and development, and the growing acceptance of fertility treatments. In June 2022, AIVF, an Israeli healthtech startup specializing in AI-driven in-vitro fertilization (IVF) solutions, raised USD 25 million in Series A funding led by Insight Partners, with participation from Adam Neumann's Family Office.

Fertility refers to the ability of an individual or a population to reproduce. In biological terms, it refers to the capacity to conceive and give birth to offspring. Fertility is often measured by the number of children born to a woman during her lifetime, but it can also be looked at from a broader societal level, considering birth rates and reproductive health. Factors influencing fertility include genetics, age, health, lifestyle, environmental conditions, and access to healthcare. Issues like infertility, which can be caused by various medical conditions, lifestyle choices, and age-related factors, have led to the growing demand for fertility treatments. Technologies such as In Vitro Fertilization (IVF) and other assisted reproductive technologies (ART) have provided new opportunities for individuals struggling with fertility challenges. Fertility is an important part of human biology, and its study is crucial for understanding population dynamics, public health, and societal growth.

Report Highlights

• North America holds the largest share of the global fertility market, accounted 54.93% in 2023.
• Europe has hit second position and accounted for 19.67% of the total revenue share in 2023.
• By offering, the assisted reproductive technology (ART) segment has captured largest revenue share of 86.76% in 2023.
• By end user, the fertility clinics segment has generated revenue share of 73.81% in 2023.

Fertility Market Growth Factors

• Ovarian Rejuvenation Techniques: One of the primary causes of female infertility is the aging of the ovaries. Ovarian rejuvenation techniques have been devised by researchers in recent years to reverse the effects of aging on the ovaries. An example of this approach is the injection of platelet-rich plasma (PRP) into the ovaries to promote the development of new follicles. The positive results of clinical trials on ovarian rejuvenation give hope to women experiencing age-related infertility. An increased chance of conceiving naturally and extending reproductive life can be the outcome of the treatment.
• Increasing Acceptance of Stem Cell Therapy: Stem cell therapy is one of the cutting-edge treatment methods for treating infertility. Many researchers are investigating the potential use of stem cells in repairing and regenerating reproductive tissues. This gives hope to those with infertility-related medical conditions that were once thought to be incurable. Clinical trials are currently in progress in 2024 to examine the potential of stem cells to regenerate ovarian function in women with premature ovarian failure and to heal damaged testicular tissue in men. While these treatments are still in the experimental phase, the initial results are encouraging and have the potential to accelerate the development of novel fertility therapies.
• Expanded Access to Fertility Treatments: Fertility treatments are becoming widely available due to developments in telemedicine and digital health. By 2024, more patients were expected to have access to high-quality reproductive care owing to monitoring, counseling, and remote consultations. Telemedicine is easing things by being more convenient and flexible, especially for patients who live in underserved or remote areas. Furthermore, telemedicine provides enhanced and seamless care with individual support and attention during the entire course of fertility treatments.

Fertility Market Trends

• Genomic Medicine and Personalized Fertility Treatments: Among the most promising areas of advancement is the use of genomic medicine in treating infertility. By studying the genetic composition, the treatment can be customized to the patient's specific genetic profile. This personalization increases the chance of success of fertility treatments and minimizes complications. In 2024 there has been growing advancement and rise in accessibility of genomic screening. Preimplantation genetic diagnosis (PGT) has undergone significant advancements, which makes detecting genetic abnormalities in embryos more precise. In the end, selecting the healthiest embryos for implantation is likely to increase the chances of a successful pregnancy.
• Enhanced Cryopreservation Techniques: One of the critical steps in the fertility treatment procedure is the technique of cryopreservation of embryos and gametes. The enriched quality of preserved eggs, sperm, and embryos has been facilitated by the recent advancements in cryopreservation procedures, thereby resulting in higher survival rates. The success rates of thawed embryos are also expected to be amplified by using the recent advancements in vitrification. By doing so, the survival of more embryos is guaranteed during the freezing and thawing procedure. Therefore, it is anticipated that the survival of a greater number of embryos will enhance the efficacy and adaptability of fertility treatments.
• Microfluidics and Lab-on-a-Chip Technologies: Fertility treatments are being transformed with the use of advanced technologies such as microfluidics and lab-on-a-chip technologies. These technologies allow the manipulation of gametes and embryos in a more precise and efficient way since they permit the control of small quantities of fluid. Microfluidic devices can be employed for enhancing proper sperm classification and thereby selecting the highest quality sperm that would be used for fertilization. Additionally, lab-on-a-chip platforms help in optimizing the IVF process, which in turn reduces error rates and increases efficiency.

Report Scope

Fertility Market Dynamics

Drivers

Increased Use of Non-Invasive Prenatal Tests

• A noninvasive prenatal test (NIPT) involves a blood test and is an accurate screening test. This test can help detect chromosomal abnormalities in developing babies. This blood test is performed in the first trimester of pregnancy. The early developmental and overall health of the unborn child can be studied and analyzed by the use of advanced NIPT. It can also be used for screening of diseases like Down syndrome, Patau syndrome, Turner syndrome, and Edward syndrome, in the baby, which is a very effective and safe procedure.

Growing Adoption of Holistic and Integrative Approaches

• While new technologies are driving the market for fertility treatment, integrative and holistic methods are also gaining popularity nowadays. There is a rise in the use of some supportive therapies apart from advanced technologies. There is a growing demand for supporting therapies such as acupuncture, yoga, and nutritional counseling. The fertility clinics are now readily including these therapies in the treatment plan itself. Such integrative approaches support the overall well-being of the patient and help in reducing stress, which can have a positive impact on fertility. By considering the physical, emotional, and mental aspects of infertility, clinics are now looking forward to providing more comprehensive care to their patients.

Restraints

High Costs of the Procedures

• The high cost of ART treatments has led to staggering global prejudice in access, even though infertility rates are similar around the world. In more than half of the low- and middle-income countries examined in a systematic review, the direct cost of an ART cycle was higher than the average annual gross domestic product per capita. Inequalities are also seen within countries based on geography, socioeconomic status, and ethnicity.

Regulatory Compliance

• Fertility clinics must comply with a variety of laws enacted by both the federal government and individual states. These requirements include those related to patient privacy (HIPAA), laboratory and diagnostic standards, and ethical norms. The Society for Assisted Reproductive Technology (SART) also has strict data reporting requirements, such as assisted reproductive cycles and IVF success rates. It can be difficult for staff to meet compliance requirements while monitoring the revenue cycle.

Opportunities

Growing Robotic-Assisted Reproductive Surgery

• Robotic assistance in reproductive surgery tends to lead to higher success rates and accuracy. Therefore, robotic systems are being used in surgical procedures like myomectomy (removal of uterine fibroids) and tubal reanastomosis (reversal of tubal ligation). These minimally invasive surgical procedures have several benefits that include improved surgical outcomes, a shorter recovery period, and a lower risk of complications. Surgical interventions for fertility treatment are growing owing to the benefits provided by robotic-assisted techniques.

Rising Epigenetic Modifications

• New approaches to fertility treatments are being made possible by the field of epigenetics. Epigenetics is the study of making changes in gene expression without changing the underlying DNA sequence. There are ongoing investigations on the potential impact of epigenetic modifications on reproductive health and related treatment outcomes. The goal of the research is to find epigenetic markers that indicate a patient's reaction to infertility treatments. By understanding these markers, the physicians can optimize treatment outcomes by modifying protocols. In addition, epigenetic treatments are further being developed to enhance the quality of sperm and eggs, thereby increasing the chances of fertility.

Challenges

Treating Poor Responders

• One of the unmet needs in females while treating infertility is the treatment of poor responders. Poor responders are the patients who exhibit a low ovarian response to ovarian stimulation during IVF treatment. In comparison to women who respond normally to treatment, the poor responders have lower success rates which leads to discontinuation of treatment many times. To increase the likelihood of successful pregnancy in poor responders there is a requirement for new treatments.

Limited Success Rate

• Factors such as hormonal, physiological, and genetic problems, can be the reasons leading to infertility, and therefore determining the root cause can be difficult. Several reasons tend to cause disparities in success rates, such as lifestyle decisions, overall health, and the underlying causes of infertility. Fertility has also been known to be impacted by stress, and infertility treatments can be emotionally taxing. Therefore, owing to such factors the success rate of treatments may vary from person to person.

Fertility Market Segmental Analysis

The fertility market is segmented into type, offering, end-users and region. Based on type, the market is classified into male fertility, and female fertility. Based on offering, the market is classified into assisted reproductive technology (ART), and fertility drugs. Based on end-users, the market is classified into fertility clinics, hospitals, and clinical research institutes.

Type Analysis

Male Fertility: Inadequate physical activity and nutrition are among some of the many factors that are affecting male fertility. In cases where there is a low sperm count or issues related to motility, treatments like intracytoplasmic sperm injection (ICSI) are considered worldwide. Owing to the high success rate, provided by the ICSI procedure—which involves directly injecting sperm into an oocyte or egg—is growing in popularity among patients. Infections or hormonal imbalances are two of the specific causes of male infertility that can be treated with a variety of drugs and hormone therapies. These treatments are also considered to be effective solutions for male infertility.

Female Fertility: Medical conditions such as polycystic ovary syndrome (PCOS), endometrial tuberculosis, and sexually transmitted diseases (STDs) are some of the reasons leading to infertility in females. In addition, to the above medical conditions deterioration of egg quality in women because of delayed pregnancy also contributes to the rise in female infertility rates. The average age at which women and men get married and have their first child has increased. This trend is now clearly pronounced as more people are pursuing higher education and are career-oriented.

Offering Analysis

ART: The assisted reproductive technologies (ART) segment has captured largest revenue share of 86.76% in  2023. For several reasons, assisted reproductive technologies (ART) are leading the fertility industry. IVF with intracytoplasmic sperm injection (IVF with ICSI), intrauterine insemination (IUI), and IVF without intracytoplasmic sperm injection (IVF without ICSI) are some of the few ART methods used for treating infertility. The success rates of ART procedures have grown as a result of growing technological advancements, particularly in the field of IVF. A rise in the adoption and acceptance of ART as a way to get pregnant in the infertile population further contributes to its dominance. Both developing and developed nations have a growing number of reproductive clinics and facilities that are offering these cutting-edge services. All these factors make ART the largest procedure segment of the infertility treatment market and this is likely to continue in the future.

Fertility Drugs: In 2023, the fertility drugs segment has accounted 13.24% of the total revenue share. Fertility drugs are expected to contribute positively to the market and the availability of various products to treat these conditions. The procedure of in vitro fertilization (IVF) involves fertilizing an egg outside of the body, and this procedure is becoming very common and is thus predicted to propel market expansion. Further, innovative medications are being introduced by market players for treating infertility. Currently, Oxolife (OXO-001), a first-in-class product candidate aims to improve embryo attachment to the uterine lining by promoting a stronger binding. In addition, the American biopharmaceutical business Ferring Pharmaceuticals unveiled a drug Trisequens, which is a novel medication prescribed for female infertility.

End-Users Analysis

Fertility Clinics: The fertility clinics segment has held dominating postion in 2023, accounted for 73.81%. Fertility clinics offer a wide range of treatments such as IVF, ICSI, egg and sperm donation, fertility preservation, and genetic testing. Their ability to provide a full spectrum of services under one roof makes them the first choice for patients. Fertility clinics are providing individualized treatment plans to meet the unique needs of each patient which in turn maximizes patient satisfaction. These clinics have specialized reproductive medicine professionals on their list of staff, consisting of fertility counselors, embryologists, and genetic specialists, who guarantee high-quality care. To perform all the complex procedures fertility clinics are well-equipped with state-of-the-art technology and laboratories.

Hospitals: The hospital segment has captured revenue share of 18.29% in 2023. Hospitals provide a wide range of medical services, which also include reproductive health care. Family planning, obstetric and gynecological care, and prenatal care are among the few services that are included in the category of reproductive care. Additionally, hospitals offer a wide range of medical services to meet different healthcare needs. However, the scope of reproductive services in hospitals varies by facility.

Clinical Research Institutes: The clinical research institutes segment has captured revenue share of 7.90% in 2023. Clinical research institutes play a major role in the commitment to innovation in infertility treatment. The goal of research institutes is to advance fertility treatment through groundbreaking research. Success is based on practicing and developing medicine of the highest quality and rigorous evidence base by conducting fertility research and collaborating with other leading institutions in the field of reproductive medicine.

Fertility Market Regional Analysis

What factors contribute to North America's leadership in the fertility market?

The North America fertility market size was estimated at USD 21.14 billion in 2023 and is expected to reach around USD 40.78 billion by 2033. The infertility treatment market is being further stimulated by the increasing number of fertility clinics in the United States. The establishment of these facilities throughout the nation is a direct result of the growing awareness of infertility issues among a significant number of individuals and couples, which has resulted in a demand for treatment services that are specifically designed to address this issue.

The expansion of fertility clinics is facilitating the process of seeking assistance and enhancing access to treatment for patients. The success rates of these clinics are increasing as a result of the advancements in medical practices and technology. Consequently, a growing number of patients are seeking treatment. Increasing fertility clinics and a rise in the number of people who are seeking reproductive services in the area are two main indicators of shifting social norms.

Europe Fertility Market Trends

The Europe fertility market size was reached at USD 7.57 billion in 2023 and is projected to surpass around USD 14.60 billion by 2033. In Europe, the demand for fertility treatments has increased drastically in recent years. Many factors, that include rising infertility rates, delaying parenthood, and shifting lifestyle preferences, are adding up to this trend. The laws regarding fertility treatment differ throughout Europe. Certain countries have more lenient legislation, facilitating a wider array of reproductive services, whereas others enforce some stringent regulations.

Advanced reproductive therapy (ART) and basic fertility examinations are two of the many services provided by the many fertility clinics in Europe. In most cases, these clinics provide specialized care and support to individuals or couples in need of reproductive therapy. Due to differences in laws & regulations and costs among European nations, few individuals opt for cross-border reproductive treatment, requiring travel to another country for reproductive care.

Why is Asia-Pacific region witnessing strong growth in fertility market?

The Asia-Pacific fertility market size was worth USD 6.10 billion in 2023 and is predicted to hit around USD 11.76 billion by 2033. The demand for fertility treatment has increased as a result of lifestyle changes, delayed reproduction, and an increase in infertility cases. Advances in assisted reproductive technologies (ART), such as intracytoplasmic sperm injection (ICSI), preimplantation genetic diagnosis (PGT), and in vitro fertilization (IVF), have increased the availability and efficacy of fertility treatments. People can now afford fertility treatments more easily owing to financial aid or subsidies from various governments in the Asia-Pacific.

The de-stigmatization of infertility and high knowledge related to reproductivity and available treatments have further led to an increase in the number of people seeking assistance. ART laws are still being updated in many countries in the Asia Pacific to improve their inclusivity and accessibility to a larger group of individuals.

LAMEA Fertility Market Growth

The LAMEA fertility market was valued at USD 3.68 billion in 2023 and is anticipated to reach around USD 7.10 billion by 2033. Rising population suffering from infertility, low-cost healthcare facilities, and rising disposable income all contribute to market growth. Furthermore, the market is expected to profit from the introduction of new and more permissive rules that allow single people and LGBTQ+ couples to receive fertility treatments. Private clinics accounted for about 90.1% of all services provided in Brazil, according to the National Library of Medicine, making them a major provider in the Brazilian market. Due to the scarcity of insurance and funding options, access to these treatments is typically conditioned upon an individual's financial circumstances.

However, due to rising healthcare costs, research, and technological advancements, the Middle East's market expansion offers new growth opportunities. Additionally, advancements in ART, amplified public awareness regarding infertility treatments, and a rise in the number of IVF clinics are said to promote the growth of fertility services.

The South African market is witnessing growth; however, it remains constrained and challenging to access for a significant segment of the population due to high costs and limited availability, particularly in the public sector. Improving access to affordable fertility services could effectively meet unmet needs.

Fertility Market Top Companies

• Boston IVF Fertility Clinic
• INVO Bioscience
• San Diego Fertility Center
• Celmatix
• FUJIFILM IRVINE SCIENTIFIC
• Thermo Fisher Scientific
• AB Scientific Ltd.
• Rocket Medical PLC
• Vitrolife
• Merck KGaA (EMD Serono Inc.)
• IVFtech APS
• Hamilton Thorne Ltd.
• Esco Micro Pte Ltd.
• Genea Biomedx Ltd.
• Carolinas Fertility Institute
• Progyny Inc.
• Cook Medical
• LifeGlobal Group (Cooper Surgical)
• Oxford Gene Technology (Sysmex Corporation)
• King’s Fertility Limited
• Monash IVF Group

The global market is highly competitive and includes various SMEs and large companies including Autodesk, Siemens, Rockwell Automation, and ABB Group. Agreements, acquisitions, mergers, and contracts are some of the key strategies adopted by these companies. Moreover, the companies give great importance to using cutting-edge technologies in software for smart manufacturing applications. In June 2022, Mankind Pharma developed and launched a generic version of Dydrogestrone tablets for the treatment of pregnancy-related complications in patients in India. This drug was an equivalent version of Abbott Duphaston tablets.

CEO Statements

Dr. Somesh Mittal, CEO of ART Fertility Clinics

" India needs global standard assisted reproduction and ART Fertility Clinics brings the right kind of expertise and advancement to it. They adhere to the highest clinical practice standards and patient care protocols that match the best in class from the world while maintaining the highest ethical standards. The highly qualified doctors, with international peer-reviewed original research papers in their names, are known for their professional excellence in patient care."

Tammy Sun, CEO and Co-founder, Carrot

"Fertility care is complex, and patients are often left on their own to make care decisions based on limited knowledge, this lack of education can lead to unnecessary treatments, worsening the patient experience without improving outcomes."

Recent Developments

Key players in the fertility market are pivotal in delivering a variety of innovative construction solutions, such as prefabrication techniques, sustainable materials, and advanced digital technologies. Some notable developments in the fertility industry include:

• In August 2024, Birla Fertility & IVF completed the acquisition of BabyScience IVF Clinics. BabyScience IVF Clinics is based in Bengaluru and operates primarily in cities in South and West India such as Mumbai, Bengaluru, and Chennai. The company has 12 clinics in Maharashtra, Karnataka, Tamil Nadu, Delhi and Haryana. The acquisition marks Birla Fertility & IVF's entry into three new states.
• In February 2024, Ganirelix Acetate Injection, which is designed to prevent early surges in luteinizing hormone in women, was launched in the US on Thursday, according to a press release from Lupin Ltd. The pharmaceutical company informed the exchanges that the US Food and Drug Administration (USFDA) has given it the green light to launch Ganirelix Acetate Injection in the country.
• In January 2024, Indira IVF, a network of infertility treatment clinics, announced its international foray with the opening of its hospital in Kathmandu, Nepal. This marks the organization's first step beyond Indian borders and ushers in its next phase of growth.

These advancements mark a notable expansion in the fertility market, driven by strategic acquisitions and innovative projects. The focus is on boosting sustainability, enhancing construction efficiency, and broadening product offerings to meet diverse building needs.

Market Segmentation

By Type

• Male Fertility
• Female Fertility

By Offering

• Assisted Reproductive Technology (ART)
  • IVF
  • Artificial Insemination
  • Surrogacy
  • Others
• Fertility Drugs
  • Gonadotropin
  • Anti-estrogen
  • Others

By End-Users

• Fertility Clinics
• Hospitals
• Clinical Research Institutes

By Region

• North America
• Europe
• APAC
• LAMEA